Cynapsus Therapeutics (CYNA), MonoSol Enter Licensing Agreement

 

Cynapsus Therapeutics Inc. (Nasdaq: CYNA), and MonoSol Rx LLC announced that they have signed a global licensing agreement for certain intellectual property (“IP”) including existing patents, patent applications, and future patents and patent applications covering all oral films containing apomorphine for the treatment of OFF episodes in Parkinson’s disease (“PD”) patients.

Subscribe to get the latest news